Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

NCT02075255 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

BIOLOGICAL: Benralizumab
BIOLOGICAL: Placebo
BIOLOGICAL: Benralizumab

Sponsor

AstraZeneca